¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"B cell receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® muscle cell(=muscle fiber) ÇÑ±Û ±ÙÀ°¼¼Æ÷
¼³¸í   
  ±ÙÀ°Àº ¼öÀDZÙ(ÀǽĿ¡ ÀÇÇØ¼­ Á¶ÀýÀÌ °¡´ÉÇÑ ±ÙÀ°: ¿¹¸¦ µé¾î ´Ù¸®, ÆÈ, ¾ó±¼±ÙÀ° µî)°ú ºÒ¼öÀDZÙ(Àǽİú ¹«°üÇϰԠÁ¶ÀýÇÏÁö ¾Ê¾Æµµ ¿òÁ÷À̴ ±ÙÀ°: ¿¹¸¦ µé¾î ½ÉÀå±Ù, ¼ÒÈ­±â°ü¿¡ ºÐÆ÷Çϴ ±ÙÀ° µî)À¸·Î ³ª´©¾îÁö¸ç, ±ÙÀ°¼¼Æ÷ÀÇ ¸ð¾çÀº ´ÙÀ½°ú °°´Ù(¼öÀDZÙ, ºÒ¼öÀDZ٠¿Ü¿¡ ½ÉÀå¿¡ Àִ ½ÉÀå±ÙÀº ºÒ¼öÀDZٿ¡ ÇØ´çÇÏÁö¸¸ ±× ¸ð¾çÀº ¼öÀDZٰú °°¾Æ µû·Î ºÐ·ùÇÑ´Ù).
  
  ±ÙÀ°¼¼Æ÷
¿µ¹® white blood cell(WBC), leukocyte ÇÑ±Û ¹éÇ÷±¸
¼³¸í   
  Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, È¤Àº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀΠÇö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù.
¿µ¹® mast cell ÇÑ±Û ºñ¸¸ ¼¼Æ÷
¼³¸í   
  µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷Çϴ ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀǠǥ¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼­·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ È­ÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù.
¿µ¹® cell ÇÑ±Û ¼¼Æ÷
¼³¸í   
  »ý¸íü¸¦ ÀÌ·ç´Â ±¸Á¶Àû, ±â´ÉÀû ´ÜÀ§.
  
  ÇÙÀÇ À¯¹«¿¡ µû¶ó¼­ À¯ÇÙ¼¼Æ÷¿Í ¹«ÇÙ¼¼Æ÷·Î ³ª´­ ¼ö°¡ ÀÖ´Ù. ¹«ÇÙ¼¼Æ÷¶õ ÇÙÀÌ ¾ø´Â ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. ÇÙÀ̶õ À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ ¿°»öü¸¦ º¸°üÇϴ °÷Àε¥ ¹«ÇÙ¼¼Æ÷¿¡¼­´Â ¿°»öü°¡ ¼¼Æ÷¼Ó¿¡ ±×³É ³ëÃâµÇ¾î ÀÖ´Ù. ´ë°³ ¼¼Æ÷ ÇϳªÇϳª°¡ µ¶¸³µÈ »ý¸íüÀÇ ¿ªÇÒÀ» Çϴ ´Ü¼¼Æ÷»ý¹°·Î¼­ ¿ÜºÎȯ°æÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇÒ ¼ö Àִ °ß°íÇÑ ¼¼Æ÷º®À» °¡Áö°í ÀÖ´Ù. À¯ÇÙ¼¼Æ÷¶õ ÇÙÀ» °¡Áö°í À־ À¯ÀüÁ¤º¸°¡ Àִ ¿°»öü°¡ ¼¼Æ÷ÀÇ ´Ù¸¥ ºÎºÐ°ú ±¸ºÐµÇ¾î ÇÙ¼Ó¿¡ µé¾îÀÖ´Ù. ¼¼Æ÷¼Ó¿¡¼­ ÇÙ¿ÜÀÇ ºÎºÐ(À̸¦ ¼¼Æ÷ÁúÀ̶ó ÇÑ´Ù)¿¡´Â ¿©·¯ °¡Áö ¼¼Æ÷ÀÇ ¼Ò±â°üÀÌ À־ ¼¼Æ÷ÀÇ ´Ù¾çÇÑ ±â´ÉÀ» ºÐ´ãÇÑ´Ù.
  
  ¢ÂÀ¯ÇÙ¼¼Æ÷ÀÇ ±âº» ±¸Á¶
  
  1.¼¼Æ÷¸·-¼¼Æ÷¸¦ µÑ·¯½Î¼­ ÁÖÀ§È¯°æ°ú ºÐ¸®ÇÏ¿© ¼¼Æ÷ÀÇ ³»È¯°æÀ» À¯ÁöÇÑ´Ù.
  
  2.ÇüÁú³»¼¼¸Á(endoplasmic reticulum)-´ÜÀ§¸·À¸·Î µÑ·¯½×¿© Àִ ºÒ±ÔÄ¢ÇÑ ¸Á»ó±¸Á¶ÀÌ´Ù. ÀÌ ¸Á»ó±¸Á¶ÀÇ ³»ºÎ¸¦ ¼Ò°­, ¼ÒÁ¶¶ó°í ºÎ¸¥´Ù. ¿©±â¿¡´Â Ç¥¸éÀÌ ¸Å²öÇÑ ¹«°ú¸³ÇüÁú³»¼¼¸Á°ú Ç¥¸éÀÌ ºÒ±ÔÄ¢ÇÑ °ú¸³ÇüÁú³»¼¼¸ÁÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. °ú¸³ÇüÁú³»¼¼¸ÁÀÇ °æ¿ì´Â Ç¥¸é¿¡ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¸®º¸¼ØÀ̶ó´Â °ÍÀÌ ºÎÂøµÇ¾î ÀÖ´Ù. À̰÷Àº ÁַΠ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ Àå¼ÒÀÌ´Ù. ¹«°ú¸³ÇüÁú³»¼¼¸ÁÀº Ç¥¸é¿¡ ¸®º¸¼ØÀÌ ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº °ÍÀ» ¸»Çϸç, À̰÷¿¡¼­´Â ÁÖ·Î ÇØµ¶ÀÛ¿ë, ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º, ½ºÅ×·ÎÀ̵åÈ£¸£¸óÀÇ ÇÕ¼º µîÀÌ ÀϾ´Ù.
  
  3.¸®º¸¼Ø-´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¿ªÇÒÀ» Çϴ °÷ÀÌ´Ù.À̰ÍÀº ¼¼Æ÷Áú¿¡ Á¸ÀçÇϴ ÀÚÀ¯¸®º¸¼Ø°ú °ú¸³ÇüÁú³»¼¼¸Á¿¡ ºÎÂøÀÌ µÇ¾î Á¸ÀçÇϴ ºÎÂø¸®º¸¼ØÀÇ µÎ °¡Áö·Î ³ª´«´Ù. ÀÚÀ¯¸®º¸¼ØÀº ÁַΠ¼¼Æ÷³»¿¡¼­ ÇÊ¿äÇÑ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» Ç졒ʼÎÂø¸®º¸¼ØÀº ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  4.°ñÁöÀåÄ¡(Golgi apparatus)-ÇÙÁÖÀ§¿¡ ºÐÆ÷Çϴ ³³ÀÛÇØÁø ÁָӴϸð¾çÀÇ °ÍÀÌ ÁßøµÇ¾î Çü¼ºµÈ ÃþÆÇ ¸ð¾çÀÇ ±¸Á¶¹°·Î °ú¸³ÇüÁú³»¼¼¸Á¿¡¼­ »ý¼ºµÇ¾î ¿ÜºÎ·Î ºÐºñµÉ ´Ü¹éÁúÀ» ¸ð¾Æ¼­ ³óÃà, Æ÷ÀåÇÏ¿© °ú¸³À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  5.»ç¸³Ã¼(mitochondria)-±¸Çü, ³­ÇüÀÇ ±ä ¸·´ë±â ¸ð¾çÀ¸·Î Å©±â°¡ ´Ù¾çÇÑ ±¸Á¶¹°. »ý¹°Ã¼ÀÇ ¿¡³ÊÁö ÀúÀå¹°ÁúÀΠATP¸¦ »ý»êÇϴ ¿ªÇÒÀ» ÇÑ´Ù. ¶Ç ¼¼Æ÷¿Í ´Ù¸¥ ÀڽŸ¸ÀÇ À¯ÀüÁ¤º¸¸¦ °¡Áø DNA, RNA¸¦ °¡Áö°í ÀÖ´Ù. ¸ð¾ç, Å©±â°¡ ¼¼±Õ°ú ºñ½ÁÇϸç ÀÚüÁõ½Ä¼º µî µ¶¸³µÈ »ý¸íü·Î¼­ ÇÊ¿äÇÑ ¿ä°ÇÀ» °®Ãß°í À־ ¼¼Æ÷¿Í °ø»ý°ü°è¸¦ °¡Áø µ¶¸³µÈ ¼¼Æ÷·Î »ý°¢Çϰí ÀÖ´Ù.
  
  6.¿ëÇØ¼Òü(lysosome)-ÀÛÀº ±¸ÇüÀÇ ¼Òü·Î ¿©·¯ °¡Áö ºÐÇØÈ¿¼Ò¸¦ °¡Áø´Ù. ¼¼Æ÷¿Ü°è¿¡¼­ µé¾î¿Â ¹°Áú°ú °áÇÕÇÏ¿© ±× ¹°ÁúµéÀ» ¿ëÇØÇϴ ¿ªÇÒÀ» Çϰí, ¿À·¡µÈ ¼¼Æ÷¼Ò±â°üµéÀ» Á¦°ÅÇϴ ¿ªÇÒµµ ÇÑ´Ù.
  
  7.¼¼Æ÷ÇÙ(nucleus)-±¸Çü, ³­ÇüÀ¸·Î ¼¼Æ÷ÀÇ Á߽ɿ¡ À§Ä¡ÇÑ´Ù. ÇÙ³»¿¡´Â À¯ÀüÁ¤º¸°¡ Àִ ¹°ÁúÀΠ¿°»öü°¡ Á¸ÀçÇÑ´Ù.
  
  8.Á߽ɼÒü(centrosome)-ÇÙÁÖÀ§¿¡ Á¸ÀçÇϸ鼭 ÇÙÀÇ ºÐ¿­½Ã¿¡ ¾çÂÊÀÇ ¿°»öü¸¦ ´ç±â´Â ÀÛÀº ¼¶À¯¸¦ ¸¸µå´Â ¿ªÇÒÀ» Çϴ °÷.
  
  ¼¼Æ÷
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • acidophilic cell
    È£»ê¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷, ¼¼¿±¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • cell
    ¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ģũ·ÒÀº¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GABA A receptors
    GABA A ¼ö¿ëü(áôé»ô÷)
  • GABA receptors
    GABA ¼ö¿ëü(áôé»ô÷)
  • GABAB receptors
    GABA B ¼ö¿ëü(áôé»ô÷)
  • H1 receptors
    H1¼ö¿ëü(â¥é»ô÷)
  • HT receptors
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î¼ö¿ëü
  • HT2 receptors, action of hallucinogens
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î2¼ö¿ëü
  • Hair follicle receptors
    ¸ð³¶¼ö¿ëü(Ù¾Ò¥â¥é»ô÷)
  • Hair receptors
    ¸ð¼ö¿ëü(Ù¾â¥é»ô÷)
  • Heat receptors
    ¿­¼ö¿ëü(æðâ¥é»ô÷)
  • Histamine receptors
    È÷½ºÅ¸¹Î¼ö¿ëü
  • Immunoglobulin adhesion receptors
    ¸é¿ª±Û·ÎºÒ¸° ºÎÂø(ݾó·)¼ö¿ëü
  • Irritant receptors, ventilatory responses , ventilatory responses
    Àڱؼö¿ëü(í©Ð½áôé»ô÷), È£Èí¹ÝÀÀ(û¼ýåÚãëë)
  • J receptors, ventilatory responses mediated
    J ¼ö¿ëü(áôé»ô÷), È£Èí¹ÝÀÀ(û¼ýåÚãëë)
  • Kainate receptors
    Ä«À̳×ÀÌÆ®¼ö¿ëü(áôé»ô÷)
  • Kappa receptors
    Ä«ÆÄ¼ö¿ëü(áôé»ô÷)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atrial receptors
    (½É)¹æ¼ö¿ëü(¡­áôé»ô÷)
  • atrial receptors
    ½É¹æ¼ö¿ëü(¡­áôé»ô÷).
  • down-regulation (of receptors)
    (¼ö¿ëü)ÇÏÇâÁ¶Àý.
  • down-regulation (of receptors)
    ¼ö¿ëü(áôé»ô÷)ÇÏÇâÁ¶Àý(ù»ú¾ðàï½).
  • presynaptic receptors
    ½Å°æÁ¢ÇÕÀü ¼ö¿ëü
  • receptors
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • bronchiolar cell clara cell
    ¼¼±â°üÁö¼¼Æ÷
  • cell to cell cooperation
    ¼¼Æ÷°£ÇùÁ¶ÀÛ¿ë(á¬øàÊàúððàíÂéÄ).
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • clear cell basal cell carcinoma
    Åõ¸í¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • clear cell epinephrine cell
    ¹àÀº¼¼Æ÷ ¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • dark cell norepinephrine cell
    ¾îµÎ¿î¼¼Æ÷ ³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷(Á¦1Çü»ç±¸¼¼Æ÷)
  • Clear cell [Epinephrine cell]
    ¹àÀº¼¼Æ÷ [¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷(¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Sustentacular cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
  • Secretory epithelial cell [Glandular cell]
    ºÐºñ»óÇǼ¼Æ÷ [»ù¼¼Æ÷]
    [¿¾ ¿ë¾î] ºÐºñ»óÇǼ¼Æ÷
  • Interstitial cell [Dark cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Interstitial cell [Leydig`s cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excretory cell
    ¹è¼³¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
  • G cell G
    ¼¼Æ÷
  • germ cell
    ¹è¼¼Æ÷
  • interstitial plasma cell pneumonia
    °£Áú¼ºÇüÁú¼¼Æ÷Æó¿°
  • nurse cell
    º¸¸ð¼¼Æ÷
  • renette cell
    ¹è¼³¼¼Æ÷
  • tegumental cell
    Ç¥ÇǼ¼Æ÷
  • vitelline cell
    ³­È²¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption cell
    Èí¼ö¼Ò°ü (ýåâ¥á³Î·)
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AChRs Acetylcholine Receptors
RA radioactive; ragocyte; ragweed antigen; rapidly adapting [receptors]; reactive arthritis; reciprocal...
MC mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med...
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
GC ganglion cell; gas chromatography; general circulation; general closure; general condition; generali...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
KIR Killer cell Ig-like Receptors
KIR Killer cell Immunoglobulin-like Receptors
AR Alpha1-adrenergic receptors
alpha1-ARs Alpha1-adrenergic receptors
beta 2AR Beta 2-adrenergic receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • Abbe-Zeiss counting cell
    ¾Ðº£-ÀÚÀ̽º Ç÷±¸ °è»ê
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • absolute cell increase
    Àý´ë ¼¼Æ÷ ¼ö Áõ°¡
  • absorptive cell
    Èí¼ö ¼¼Æ÷
  • accessory cell
    ºÎ¼¼Æ÷
    °ñÀú¼± Áß¿¡¼­ ÁÖ¼¼Æ÷, ¹æ¼¼Æ÷¿¡ ¼¯¿©¼­ Á¸ÀçÇÑ´Ù. ÀÔ¹æÇüÀ̸ç Á¡¾×¼ºÀÇ ¹°ÁúÀ» °£Á÷ÇÑ´Ù. ÇÙÀº ¼¼Æ÷Àú¿¡ Ä¡¿ìÃÄ ÀÖ¾î ÆíÆò¿¡ °¡±õ´Ù.
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adipose cell
    Áö¹æ ¼¼Æ÷
    Áö¹æÀ» °¡Áø ¼¼Æ÷·Î¼­ ¼¼Æ÷´Â ±¸ÇüÀ» ÀÌ·ç°í, ÇÙÀº ÇÑ ÂÊÀ¸·Î Ä¡¿ìÃÄ ÀÖ´Ù.
  • adrenal medullary chromaffin cell
    ºÎ½Å ¼öÁú Å©·Ò ģȭ ¼¼Æ÷
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
B-cell antigen receptors In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors.
(05 Mar 2000)
receptors, antigen, B-cell Immunoglobulin molecules on the surface of B-lymphocytes that recognise and bind antigen.
(12 Dec 1998)
receptors, antigen, T-cell Molecules on the surface of T-lymphocytes that recognise and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (antigens, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (receptors, antigen, T-cell, alpha-beta) or gamma-delta (receptors, antigen, T-cell, gamma-delta) chains.
(12 Dec 1998)
receptors, antigen, T-cell, alpha-beta T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognise antigens only when presented in association with major histocompatibility (MHC) molecules.
(12 Dec 1998)
receptors, antigen, T-cell, gamma-delta T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see antigens, CD3).
(12 Dec 1998)
receptors, cell surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behaviour of the target cell. Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
(12 Dec 1998)
T-cell antigen receptors Receptors present on T-cells that interact with both processed antigen and major histocompatibility antigens simultaneously.
(05 Mar 2000)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
adrenergic receptors Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents.
Synonym: adrenoceptor, adrenoreceptors.
(05 Mar 2000)
alpha-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles.
(05 Mar 2000)
ANP clearance receptors Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action.
(05 Mar 2000)
ANP receptors Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains.
(05 Mar 2000)
beta-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2).
(05 Mar 2000)
mannose-6-phosphate receptors Receptors in Golgi apparatus to which newly synthesised proteins that are destined to enter lysosomes bind.
(05 Mar 2000)
receptors, adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell
    ¼¼Æ÷
  • HeLa cell
    Èú·¯ ¼¼Æ÷(¿¬±¸¿ëÀ¸·Î ¹è¾çµÇ°í ÀÖ´Â ¾Ï¼¼Æ÷ÀÇ ÀÏÁ¾)
  • blood cell
    Ç÷±¸
  • brain cell
    ³ú½Å°æ¼¼Æ÷
  • cadmium cell
    Ä«µå¹Å ÀüÁö
  • cell
    ÀÛÀº¹æ;¾ÏÀÚ(¼öµµ¿ø ºÎ¼ÓÀÇ);»ç½Ç;¿ÀµÎ¸·Áý;¹«´ý;(±³µµ¼ÒÀÇ)µ¶¹æ;(¹úÁýÀÇ)±¸¸Û;²É°¡·çÁÖ¸Ó´Ï;ÀüÁö;¼¼Æ÷;(Á¶Á÷³»ÀÇ)ÀÛÀº °øµ¿;¼¼Æ÷(°ø»ê´ç µîÀÇ);°¡½ºÅë(±â±¸ÀÇ);ºñÆ®ÀÇ ±â¾ï¼ÒÀÚ;µ¶¹æ»ìÀÌÇÏ´Ù;ÀÛÀº ¹æ¿¡ Ʋ¾î¹ÚÈ÷´Ù
  • cell body
    ¼¼Æ÷ÀÇ
  • cell cycle
    ¼¼Æ÷ÁÖ±â;ºÐ¿­ÁÖ±â
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á